中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
4期
531-532
,共2页
肝炎,乙型%恩替卡韦%苦参素
肝炎,乙型%恩替卡韋%苦參素
간염,을형%은체잡위%고삼소
Hepatitis B%Entecavir%Oxymatrine
目的 观察恩替卡韦联合苦参素治疗慢性乙型肝炎(乙肝)的临床疗效.方法 选择慢性乙肝患者74例,随机分为两组.观察组40例采用恩替卡韦片0.5 mg/d,口服,联合苦参素600 mg/d,静脉注射治疗；对照组34例仅服用恩替卡韦片0.5 mg/d.从治疗开始后1、3、6、9、12个月及随访期每半年复查血清HBeAg、Anti-HBe及丙氨酸氨荃转移酶(ALT)复常率.结果 治疗开始后1、3、6、9、12个月及随访期每半年,观察组患者血清HBeAg及Anti-HBe转阴率分别为32.5％ 、45.0％、60.0％、60.0％、62.5％、62.5％和62.5％,均高于对照组的5.9％、5.9％、8.8％、11.8％、11.8％、11.8％和11.8％ (x2 =5.46,12.83,25.22,21.68,24.79,24.79,24.79,均P＜0.05).观察组ALT复常率分别为45.0％、67.5％、87.5％、90.0％、90.0％、90.0％和90.0％,均高于对照组的20.6％、32.4％、41.2％、50.0％、52.9％、52.9％和52.9％(x2=4.60,10.36,20.67,14.47,12.08,12.08,12.08,均P＜0.05).结论 恩替卡韦联合苦参素用以治疗慢性乙肝具有协同抗病毒作用,治疗效果好、安全性高、治疗方案简单、值得临床推广使用.
目的 觀察恩替卡韋聯閤苦參素治療慢性乙型肝炎(乙肝)的臨床療效.方法 選擇慢性乙肝患者74例,隨機分為兩組.觀察組40例採用恩替卡韋片0.5 mg/d,口服,聯閤苦參素600 mg/d,靜脈註射治療；對照組34例僅服用恩替卡韋片0.5 mg/d.從治療開始後1、3、6、9、12箇月及隨訪期每半年複查血清HBeAg、Anti-HBe及丙氨痠氨荃轉移酶(ALT)複常率.結果 治療開始後1、3、6、9、12箇月及隨訪期每半年,觀察組患者血清HBeAg及Anti-HBe轉陰率分彆為32.5％ 、45.0％、60.0％、60.0％、62.5％、62.5％和62.5％,均高于對照組的5.9％、5.9％、8.8％、11.8％、11.8％、11.8％和11.8％ (x2 =5.46,12.83,25.22,21.68,24.79,24.79,24.79,均P＜0.05).觀察組ALT複常率分彆為45.0％、67.5％、87.5％、90.0％、90.0％、90.0％和90.0％,均高于對照組的20.6％、32.4％、41.2％、50.0％、52.9％、52.9％和52.9％(x2=4.60,10.36,20.67,14.47,12.08,12.08,12.08,均P＜0.05).結論 恩替卡韋聯閤苦參素用以治療慢性乙肝具有協同抗病毒作用,治療效果好、安全性高、治療方案簡單、值得臨床推廣使用.
목적 관찰은체잡위연합고삼소치료만성을형간염(을간)적림상료효.방법 선택만성을간환자74례,수궤분위량조.관찰조40례채용은체잡위편0.5 mg/d,구복,연합고삼소600 mg/d,정맥주사치료；대조조34례부복용은체잡위편0.5 mg/d.종치료개시후1、3、6、9、12개월급수방기매반년복사혈청HBeAg、Anti-HBe급병안산안전전이매(ALT)복상솔.결과 치료개시후1、3、6、9、12개월급수방기매반년,관찰조환자혈청HBeAg급Anti-HBe전음솔분별위32.5％ 、45.0％、60.0％、60.0％、62.5％、62.5％화62.5％,균고우대조조적5.9％、5.9％、8.8％、11.8％、11.8％、11.8％화11.8％ (x2 =5.46,12.83,25.22,21.68,24.79,24.79,24.79,균P＜0.05).관찰조ALT복상솔분별위45.0％、67.5％、87.5％、90.0％、90.0％、90.0％화90.0％,균고우대조조적20.6％、32.4％、41.2％、50.0％、52.9％、52.9％화52.9％(x2=4.60,10.36,20.67,14.47,12.08,12.08,12.08,균P＜0.05).결론 은체잡위연합고삼소용이치료만성을간구유협동항병독작용,치료효과호、안전성고、치료방안간단、치득림상추엄사용.
Objective To observe the clinical effect of entecavir combined with oxymatrine in the treatment of patients with hepatitis B.Methods 74 patients with hepatitis B were randomly divided into two groups.The treatment group(40 cases) were given entecavir 0.5mg daily,oxymatine 600mg,intravenous daily.The control group (34 cases) were given entercavir 0.5mg daily.The HBeAg and Anti-HBe negative conversion rates,the HBV-DNA negative conversion rate and the ALT normalization rate after 1,3,6,9,12 months in treatment period and 6,12months in follow-up period were observed.Results After 1,3,6,9,12 months in treatment period and 6,12 months in follow-up period,the HBeAg and Anti-HBe negative conversion rates of the treatment group was 32.5％,45.0％,60.0％,60.0％,62.5％,62.5％ and 62.5％,while that of the control group was 5.9％,5.9％,8.8％,11.8％,11.8％,11.8％ and 11.8％,there was significant difference between them( x2 =5.46,12.83,25.22,21.68,24.79,24.79,24.79,all P ＜0.05).The ALT normalization rate of the treatment groups was 45.0％,67.5％,87.5％,90.0％,90.0％,90.0％ and 90.0％,while that of the control group was 20.6％,32.4％,41.2％,50.0％,52.9％,52.9％ and 52.9％,there was significantly difference between them ( x2 =4.60,10.36,20.67,14.47,12.08,12.08,12.08,all P ＜ 0.05 ).Conclusion Entecavir combined with oxymatrine in the treatment of patients with hepatitis B had a synergistic antiviral effect,high security and simple treatment.It was worthy to promote.
